Table 3.
Outcome status of possibly, probably, or definitely F-652–related treatment emergent adverse events
| Grade 1-2 (46 events, 16 participants) | Resolved/recovering, n | Not resolved, n |
|---|---|---|
| Blood and lymphatic system disorders | ||
| Neutropenia (n = 1) | 1 | 0 |
| ENMT | ||
| Xerostomia (n = 4) | 3 | 1 |
| Dysgeusia (n = 2) | 1 | 1 |
| Gastrointestinal | ||
| LFT abnormalities (n = 13) | 11 | 2 |
| General | ||
| Chills (n = 4) | 4 | 0 |
| Malaise (n = 1) | 1 | 0 |
| Xeropthalmia (n = 1) | 1 | 0 |
| Cardiac | ||
| First-degree atrioventricular block (n = 1) | 0 | 1 |
| Metabolic | ||
| Hypercholesterolemia (n = 2) | 0 | 2 |
| Hypertriglyceridemia (n = 2) | 1 | 1 |
| Hyponatremia (n = 1) | 1 | 0 |
| Hypophosphatemia (n = 1) | 0 | 1 |
| Nervous system disorder | ||
| Paresthesia (n = 1) | 1 | 0 |
| Other | ||
| Pruritus (n = 3) | 3 | 0 |
| Skin condition (n = 3)∗ | 3 | 0 |
| Xerosis (n = 5) | 0 | 5 |
| Urinary tract infection (n = 1) | 1 | 0 |
| Grade ≥3 (22 events, 9 participants) | ||
| Blood and lymphatic system disorders | ||
| Anemia (n = 2) | 1 | 1 |
| Leukopenia (n = 3) | 1 | 2 |
| Neutropenia (n = 1) | 1 | 0 |
| Lymphopenia (n = 2) | 1 | 1 |
| Thrombocytopenia (n = 7) | 2 | 5 |
| Gastrointestinal | ||
| LFT abnormalities (n = 4) | 2 | 2 |
| General | ||
| Chills (n = 1) | 1 | 0 |
| Metabolic | ||
| Hyponatremia (n = 2) | 1 | 1 |
LFT, liver function test.
∗
Skin condition includes erythema, peeling, and stage 2 skin squamous cell carcinoma.